Director Legal Entity Planning & Forecast
About the job
- 10+ years of progressive experience across FP&A, corporate finance, accounting, controllership, transaction advisory, audit, or related finance disciplines in a complex multinational environment.
- Demonstrated experience with legal entity forecasting, statutory or entity-level planning, tax forecasting support, or integrated forecasting across FP&A, Global Tax, Treasury, and Accounting.
- Strong understanding of United States generally accepted accounting principles and consolidated financial statements, with knowledge of International Financial Reporting Standards.
- Knowledge of accounting for income taxes under ASC 740, impairment and valuation concepts, and the role of forecasts in external reporting.
- Solid understanding of intercompany transactions, transfer pricing, and how operational activity flows through legal entities.
- Experience with cash flow and liquidity forecasting and the ability to connect legal entity earnings, balance sheet movements, and cash requirements.
- Advanced financial modeling and systems skills, including advanced Excel and PowerPoint skills.
- People-management experience and the ability to influence across functions without direct authority.
- Establish and govern the enterprise Legal Entity Forecasting framework, including process design, calendar, ownership, controls, data requirements, and reconciliation to the management forecast.
- Lead the translation of management forecasts into legal entity forecasts, ensuring entity-level profit and loss, balance sheet, and cash flow projections reconcile to the consolidated FP&A outlook.
- Partner with Finance Systems and TM1 to design scalable forecasting capabilities that enable efficient capture and allocation of costs, intercompany activity, and other legal entity drivers across the enterprise.
- Provide reliable legal entity forecasts and insights to Global Tax to support tax provision, effective tax rate forecasting, tax planning, transfer pricing, impairment and valuation analysis, and other accounting-for-income-tax requirements.
- Partner with Treasury to assess legal entity liquidity and cash generation, identifying potential funding requirements, trapped cash, and implications for capital allocation and treasury risk.
- Perform regular actual-to-forecast and forecast-to-forecast variance analysis by legal entity, identifying key drivers, emerging risks, and potential implications for Global Tax, Treasury, Accounting, and management reporting.
- Establish governance and accountability across Legal Entity Finance Directors and functional teams, ensuring completeness, accuracy, timely submissions, and resolution of forecast risks.
- Provide management with actionable legal entity insights, highlighting forecast changes and emerging risks impacting Global Tax, Treasury, Accounting, and enterprise financial planning.
- CPA certification.
- Big Four audit, accounting advisory, transaction services, or similar experience.
- Experience in the pharmaceutical or biotechnology industry, including understanding of research and development, Technical Operations or manufacturing, Commercial, and Global Medical Affairs economics.
- Public-company and multinational experience, with exposure to Securities and Exchange Commission reporting.
- TM1 or Planning Analytics experience.
About the company
BeOne Medicines develops and commercializes cancer therapies for patients worldwide, focusing on hematologic cancers and solid tumors. Its products, including Brukinsa, are sold globally and supported by licensing partnerships, with internal R&D and clinical development driving a broad late-stage pipeline. BeOne differentiates itself by leveraging a large-scale clinical trial network and cost-efficient global drug development to achieve high margins while pursuing large-market indications. The company aims to expand into immunology and solid tumors while maintaining strong investment in R&D to make high-impact, accessible oncology treatments available in more than 45 countries.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
Dongcheng District, China
Founded
2010
Get referred to BeOne
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 25, 2026 FDA approval expanded TEVIMBRA in first-line HER2-positive gastroesophageal cancer.
- August 31, 2026 Phase 3 survival data strengthened ZIIHERA-containing regimens.
- Q2 2026 revenue hit $1.7 billion; management raised 2026 guidance to $6.8 billion.
What critics are saying
- BeOne accepted developed-market pricing parity and Medicaid rebates on future U.S. approvals.
- Zydus' BRUKINSA ANDA lawsuit targets patents; a 2034 composition patent remains the fortress.
- AbbVie's trade-secrets case over BGB-16673 still threatens the BTK-degrader franchise.
What makes BeOne unique
- BeOne built 35-plus assets and 93 trials across 1,100 U.S. sites by September 2026.
- BRUKINSA dominates revenue, with 2026 global sales above $1.2 billion quarterly.
- Hopewell, New Jersey gives BeOne U.S. manufacturing, R&D, and packaging capacity.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
401(k) Retirement Plan
Wellness Program
Paid Vacation
Growth & Insights and Company News
6 month growth
↑ 8%1 year growth
↓ -6%2 year growth
↓ -1%BeOne Medicines secured an exemption from Section 232 pharmaceutical tariffs through a voluntary agreement with the US government. The deal recognises over $1 billion in US manufacturing investment, including a $300 million expansion in Hopewell, New Jersey. The exemption protects BeOne from import duties on patented pharmaceuticals and ingredients. However, the company committed to pricing future FDA-approved medicines in line with other developed markets and participating in the Medicaid GENEROUS Model, which uses supplemental rebates. The Hopewell expansion will add small-molecule manufacturing and packaging capacity, creating approximately 120 full-time jobs. The facility will support a portfolio of more than 35 assets. Whilst the tariff exemption reduces supply-chain risk, international reference pricing commitments could limit pricing flexibility for future oncology medicines. Neither the tariff savings nor the financial impact of pricing concessions was disclosed.
Revolution Medicines has partnered with BeOne Medicines in a multi-part collaboration combining BeOne's oncology assets with Revolution's four clinical RAS(ON) inhibitors. The August 2026 deal grants BeOne exclusive development and commercialisation rights in select Asian markets and commits BeOne to fund a global Phase 3 trial. Revolution Medicines reported a net loss of $644.37 million in Q2 2026 and $1.1 billion over six months. The company currently generates no revenue but projects $2.3 billion in revenue and $402.5 million in earnings by 2029. The partnership shifts near-term risk by offloading Phase 3 costs whilst providing access to milestone and royalty potential. However, the core investment case remains unchanged: regulatory progress and commercialisation of daraxonrasib, with trial execution and spending presenting the biggest risks.
BeOne Medicines reported second-quarter revenue of $1.7 billion, up 30% year over year, with GAAP earnings per ADS rising 144% to $2.05. The company's BTK inhibitor BRUKINSA generated more than $1.2 billion in global sales, increasing 31% from the prior year. The company raised its 2026 revenue guidance to CNY 6.6 billion–CNY 6.8 billion and expects GAAP operating income of CNY 1 billion–CNY 1.1 billion. Free cash flow doubled year over year to CNY 435 million. BeOne received FDA approval for Beqalzi in relapsed or refractory mantle cell lymphoma and reported positive Phase III results for a chemotherapy-free BRUKINSA regimen. US BRUKINSA sales totalled $893 million, up 31%, driven by demand in chronic lymphocytic leukaemia and non-CLL indications.
John Oyler, chief executive officer of BeOne Medicines AG, sold 109,713 American Depositary Shares worth $34.6 million on 20 and 21 July 2026, according to SEC filings. The transactions were executed under a Rule 10b5-1 trading plan adopted in March 2026. Despite the sale, Oyler retains a substantial ownership position exceeding 50.4 million total shares through various holdings. These include 28.2 million shares held through Oyler Investment LLC and 9.5 million shares in a Roth IRA account. The shares were sold at a weighted average price of $315.28. BeOne Medicines is a commercial-stage oncology biopharmaceutical company with $5.7 billion in trailing twelve-month revenue and a market capitalisation of $34.2 billion.
Seegene USA has received Emergency Use Authorization from the FDA for its Allplex HSV-1&2/VZV/MPXV Assay, a multiplex real-time PCR test that simultaneously detects herpes simplex virus types 1 and 2, varicella-zoster virus, and monkeypox virus. It is the first multiplex PCR test designed to support differential diagnosis of viral causes of ulcerative skin lesions in the US market. These pathogens often present with similar clinical symptoms that are difficult to distinguish visually. Research presented at the 2024 Clinical Virology Symposium found that a multiplex PCR assay identified HSV, VZV, or MPXV in 54 out of 966 samples that had previously tested negative using single-pathogen methods. The assay was developed using Seegene's proprietary multiplex PCR technologies and automated product development platform.